LENZ Therapeutics, Inc.
NASDAQ:LENZBiotechnology
-$0.42 today
- Market cap
- $104.94M
- Beta
- 1.47
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$3.48
Volume 0.64M
Average 0.89M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
LENZ Therapeutics, Inc.
NASDAQ:LENZ
Intrinsic Alpha fair value
Locked
Current Price
$3.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +8.4% | +45.3% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +8.4% over three years. Forward estimates point to Revenue at +45.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Nanobiotix S.A. NASDAQ:NBTX | $1.53B | $30.66 | Not rated | -60.2 | +34.03% |
Tyra Biosciences, Inc. NASDAQ:TYRA | $1.38B | $20.03 | Not rated | -13.4 | -6.05% |
GH Research PLC NASDAQ:GHRS | $1.31B | $19.10 | Not rated | -23.8 | +32.67% |
Maravai LifeSciences Holdings, Inc. NASDAQ:MRVI | $1.13B | $7.54 | Not rated | -7.1 | +110.23% |
Savara Inc. NASDAQ:SVRA | $1.02B | $4.64 | Not rated | -10.6 | +11.56% |
Arbutus Biopharma Corporation NASDAQ:ABUS | $810.25M | $4.09 | Not rated | 5.4 | -3.10% |
Prime Medicine, Inc. NASDAQ:PRME | $774.48M | $4.27 | Not rated | -2.8 | +4.07% |
Geron Corporation NASDAQ:GERN | $622.98M | $0.97 | Not rated | -12.3 | -17.00% |
ARS Pharmaceuticals, Inc. NASDAQ:SPRY | $391.05M | $3.89 | Not rated | -4.8 | -50.07% |
Rezolute, Inc. NASDAQ:RZLT | $353.54M | $3.66 | Not rated | -6.5 | -56.48% |
Continue the stock analysis
Jump to another research area for this company.